90 related articles for article (PubMed ID: 21523722)
1. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
4. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
7. An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
Rose PG; Monk BJ; Provencher D; Hartney J; Legenne P; Lane S
Gynecol Oncol; 2011 Jan; 120(1):38-42. PubMed ID: 21055798
[TBL] [Abstract][Full Text] [Related]
8. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
9. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Lee DH; Kim SW; Suh C; Lee JS; Lee JH; Lee SJ; Ryoo BY; Park K; Kim JS; Heo DS; Kim NK
Ann Oncol; 2008 Jan; 19(1):123-7. PubMed ID: 17823384
[TBL] [Abstract][Full Text] [Related]
10. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.
Yamamoto R; Minobe S; Kaneuchi M; Sakuragi N; Fujimoto S; Ishizaki Y; Domon H; Hareyama H; Sato C; Fujino T; Kawaguchi I; Yamaguchi T; Fujimoto T; Yoshiaki K
Jpn J Clin Oncol; 2002 Apr; 32(4):128-34. PubMed ID: 12072422
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT
J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426
[TBL] [Abstract][Full Text] [Related]
13. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
Misawa A; Yasuda M
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
[TBL] [Abstract][Full Text] [Related]
14. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Hwang JH; Lim MC; Seo SS; Park SY; Kang S
Jpn J Clin Oncol; 2011 May; 41(5):624-9. PubMed ID: 21355002
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
